149 related articles for article (PubMed ID: 2041383)
1. (131I)meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma.
Lupoli G; Lombardi G; Panza N; Biondi B; Pacilio G; Lastoria S; Salvatore M
Med Oncol Tumor Pharmacother; 1991; 8(1):7-13. PubMed ID: 2041383
[TBL] [Abstract][Full Text] [Related]
2. The possible use of radioiodinated metaiodobenzylguanidine (MIBG) in medullary thyroid carcinoma.
Troncone L; Rufini V; Maussier ML; Valenza V; Montemaggi P; Legnaioli M
Thyroidology; 1988 Apr; (1):45-53. PubMed ID: 2484894
[TBL] [Abstract][Full Text] [Related]
3. Detection of metastatic medullary thyroid cancer with 131I-MIBG scans in Sipple's syndrome.
Itoh H; Sugie K; Toyooka S; Kawase M; Mukaino S; Hazama F; Endo K; Torizuka K; Nakao K; Imura H
Eur J Nucl Med; 1986; 11(12):502-4. PubMed ID: 2874028
[TBL] [Abstract][Full Text] [Related]
4. Thyroid uptake of MIBG in Sipple's syndrome.
Perdrisot R; Rohmer V; Lejeune JJ; Bigorgne JC; Jallet P
Eur J Nucl Med; 1988; 14(1):37-8. PubMed ID: 2898364
[TBL] [Abstract][Full Text] [Related]
5. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
[TBL] [Abstract][Full Text] [Related]
6. Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.
Poston GJ; Thomas AM; Macdonald DW; Karvounaris D; Henderson BL; George P; Lynn JA; Lavender JP
Nucl Med Commun; 1986 Apr; 7(4):215-21. PubMed ID: 2873544
[TBL] [Abstract][Full Text] [Related]
7. Uptake of 131I-MIBG by medullary carcinoma of thyroid in familial cases.
Coutris G; Talbot JN; Kabla G; Calmettes C; Milhaud G
Eur J Nucl Med; 1986; 12(2):77-9. PubMed ID: 3732310
[TBL] [Abstract][Full Text] [Related]
8. Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid.
Skowsky WR; Wilf LH
South Med J; 1991 May; 84(5):636-41. PubMed ID: 1852077
[TBL] [Abstract][Full Text] [Related]
9. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
[TBL] [Abstract][Full Text] [Related]
10. Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study.
Baulieu JL; Guilloteau D; Delisle MJ; Perdrisot R; Gardet P; Delépine N; Baulieu F; Dupont JL; Talbot JN; Coutris G
Cancer; 1987 Nov; 60(9):2189-94. PubMed ID: 2894239
[TBL] [Abstract][Full Text] [Related]
11. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine.
Clarke SE; Lazarus CR; Edwards S; Murby B; Clarke DG; Roden TM; Fogelman I; Maisey MN
J Nucl Med; 1987 Dec; 28(12):1820-5. PubMed ID: 3681441
[TBL] [Abstract][Full Text] [Related]
12. [The evaluation of 123I-MIBG scintigraphy in medullary thyroid carcinoma (MTC)].
Ahuja S; Koppenhagen K; Ernst H
Strahlenther Onkol; 1990 Nov; 166(11):718-21. PubMed ID: 2260009
[TBL] [Abstract][Full Text] [Related]
13. Medullary-thyroid-carcinoma imaging in an animal model: use of radiolabeled anticalcitonin F(ab')2 and meta-iodobenzylguanidine.
Guilloteau D; Baulieu JL; Besnard JC
Eur J Nucl Med; 1985; 11(6-7):198-200. PubMed ID: 4076227
[TBL] [Abstract][Full Text] [Related]
14. Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma.
Oishi S; Sasaki M; Sato T; Hirota Y; Takahashi M
Endocrinol Jpn; 1986 Jun; 33(3):309-15. PubMed ID: 2875869
[TBL] [Abstract][Full Text] [Related]
15. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
16. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
17. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.
Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW
J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114
[TBL] [Abstract][Full Text] [Related]
19. New tracers for the imaging of the medullary thyroid carcinoma.
Guerra UP; Pizzocaro C; Terzi A; Giubbini R; Maira G; Pagliaini R; Bestagno M
Nucl Med Commun; 1989 Apr; 10(4):285-95. PubMed ID: 2544835
[TBL] [Abstract][Full Text] [Related]
20. Localization of hepatic metastases by radiolabelled anti-carcinoembryonic antigen antibody and meta-iodobenzylguanidine in a patient with medullary thyroid carcinoma.
Liewendahl K; Välimäki M; Taavitsainen M
Eur J Nucl Med; 1993 Jun; 20(6):551-4. PubMed ID: 8339736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
